Astragaloside III has anti-gastric ulcer effects, and exhibits strong growth-promoting effects in cultured GES-1 cells. Astragaloside III can effectively reduce cancer cell survival in vitro and inhibit the tumor growth in vivo, the potential mechanism is the induction of cell apoptosis signaling pathways, suggests that it provides a new therapeutic tool to treat breast cancer. Astragaloside III is a triterpenoid saponin that is cycloastragenol with a 2-O-beta-D-glucopyranosyl-beta-D-xylopyranosyl moiety attached at position 3 via a glycosidic linkage. It is a triterpenoid saponin and a disaccharide derivative. It is functionally related to a cycloastragenol.